{"id":18879,"date":"2021-11-30T19:21:58","date_gmt":"2021-11-30T18:21:58","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=18879"},"modified":"2023-07-24T10:34:06","modified_gmt":"2023-07-24T09:34:06","slug":"5-films-inserm-sur-lantibioresistance","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/","title":{"rendered":"5 films Inserm sur l&#8217;antibior\u00e9sistance"},"content":{"rendered":"\n<p><a href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/colloque-national-antibioresistance-lundi-22-novembre-2021-aubervilliers-93\/\" target=\"_blank\" rel=\"noreferrer noopener\">Lors du colloque national sur l&#8217;Antibior\u00e9sistance<\/a>, organis\u00e9 par l&#8217;Inserm le lundi 22 novembre \u00e0 Aubervilliers, ont \u00e9t\u00e9 diffus\u00e9s 5 vid\u00e9os documentaires, r\u00e9alis\u00e9es par la soci\u00e9t\u00e9 <a href=\"https:\/\/www.lajolieprod.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">La Jolie Prod<\/a>, que vous pouvez visionner ici :<\/p>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Gilles Bloch, p-dg de l\u2019Inserm et \u00c9velyne Jouvin-Marche, coordinatrice scientifique, pr\u00e9sentent le Programme prioritaire de recherche (PPR) Antibior\u00e9sistance<\/strong> <\/h4>\n\n\n\n<p>Pourrait-on demain mourir d\u2019une infection banale faute de traitement efficace\u00a0? L&#8217;antibior\u00e9sistance est devenue un \u00e9norme probl\u00e8me de sant\u00e9 publique avec une interd\u00e9pendance entre l\u2019humain, l\u2019animal et l\u2019environnement. Avec l\u2019utilisation accrue et le m\u00e9susage des antibiotiques, et leur contamination de l\u2019environnement, les bact\u00e9ries sont devenues de plus en plus r\u00e9sistantes aux traitements\u2026<\/p>\n\n\n\n<p>En 2019, l\u2019\u00c9tat fran\u00e7ais a confi\u00e9 \u00e0 l\u2019Inserm le pilotage du PPR Antibior\u00e9sistance. Ce programme de recherche qui f\u00e9d\u00e8re l\u2019ensemble des forces fran\u00e7aises publiques et priv\u00e9es du domaine, int\u00e8gre une dimension internationale avec notamment une collaboration avec les pays \u00e0 ressources limit\u00e9es. Il propose dans une approche pluridisciplinaire \u00ab&nbsp;une seule sant\u00e9&nbsp;\u00bb (\u00ab&nbsp;<em>One Health<\/em>&nbsp;\u00bb), de nouvelles strat\u00e9gies et mesures de lutte pour inverser la courbe des r\u00e9sistances microbiennes.<\/p>\n\n\n\n<p>\u00c0 l\u2019initiative du&nbsp;minist\u00e8re de l\u2019Enseignement sup\u00e9rieur, de la Recherche et de l\u2019Innovation, et du Secr\u00e9tariat g\u00e9n\u00e9ral pour l\u2019investissement (SGPI), le PPR Antibior\u00e9sistance est dot\u00e9 de 40 millions d\u2019euros dans le cadre du troisi\u00e8me programme d\u2019investissements d\u2019avenir (PIA3).<\/p>\n\n\n\n<p>L\u2019Agence nationale de la recherche (ANR) est l\u2019op\u00e9rateur du programme.<\/p>\n\n\n\n<iframe src=\"https:\/\/pod.inserm.fr\/video\/1190-gilles-bloch-p-dg-de-linserm-et-evelyne-jouvin-marche-coordinatrice-scientifique-presentent-le-programme-prioritaire-de-recherche-ppr-antibioresistance\/?is_iframe=true\" style=\"padding: 0; margin: 0; border:0\" allowfullscreen=\"\" width=\"100%\" height=\"360\"><\/iframe>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Antibior\u00e9sistance : outils et r\u00e9seaux structurants<\/strong><\/h4>\n\n\n\n<p>Dans le Programme prioritaire de recherche (PPR) Antibior\u00e9sistance, il y a l\u2019optimisation des usages, l\u2019innovation th\u00e9rapeutique, le contr\u00f4le de l&#8217;\u00e9mergence\u2026 Mais cela ne suffit pas.<\/p>\n\n\n\n<p>Pour lutter efficacement contre l\u2019antibior\u00e9sistance, il faut aussi r\u00e9ussir \u00e0 mutualiser les connaissances et les donn\u00e9es, sortir de l\u2019isolement alors que jusqu\u2019alors chaque expert travaille dans son domaine de comp\u00e9tence, avec ses propres outils d\u00e9velopp\u00e9s pour son domaine. Il est crucial que la recherche se mette en r\u00e9seau et\u2026 s\u2019int\u00e9resse aux r\u00e9seaux sociaux&nbsp;! C\u2019est l\u2019objectif du quatri\u00e8me axe du PPR Antibior\u00e9sistance.<\/p>\n\n\n\n<p>3 des 14 projets financ\u00e9s dans le cadre du PPR Antibior\u00e9sistance pilot\u00e9 par l\u2019Inserm, pr\u00e9sent\u00e9s par leur porteur&nbsp;: Promise \u2013 Marie-C\u00e9cile Ploy, ABRomics-PF \u2013 Claudine M\u00e9digue, DOSA \u2013 Nicolas Fortan\u00e9.<\/p>\n\n\n\n<p>\u00c0 l\u2019initiative du minist\u00e8re de l\u2019Enseignement sup\u00e9rieur, de la Recherche et de l\u2019Innovation, et du Secr\u00e9tariat g\u00e9n\u00e9ral pour l\u2019investissement (SGPI), le PPR Antibior\u00e9sistance est dot\u00e9 de 40 millions d\u2019euros dans le cadre du troisi\u00e8me programme d\u2019investissements d\u2019avenir (PIA3).<\/p>\n\n\n\n<p>Ce programme de recherche qui f\u00e9d\u00e8re l\u2019ensemble des forces fran\u00e7aises publiques et priv\u00e9es du domaine, propose dans une approche \u00ab&nbsp;une seule sant\u00e9&nbsp;\u00bb, de nouvelles strat\u00e9gies et mesures de lutte pour inverser la courbe des r\u00e9sistances microbiennes. L\u2019Agence nationale de la recherche (ANR) est l\u2019op\u00e9rateur du programme.<\/p>\n\n\n\n<iframe src=\"https:\/\/pod.inserm.fr\/video\/1192-antibioresistance-outils-et-reseaux-structurants\/?is_iframe=true\" style=\"padding: 0; margin: 0; border:0\" allowfullscreen=\"\" width=\"100%\" height=\"360\"><\/iframe>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Contr\u00f4ler l\u2019\u00e9mergence de l\u2019antibior\u00e9sistance<\/strong><\/h4>\n\n\n\n<p>Pour limiter le d\u00e9veloppement de l\u2019antibior\u00e9sistance, on peut optimiser les usages, innover avec de nouveaux traitements, mais aussi faire appel aux sciences humaines et sociales.<\/p>\n\n\n\n<p>Observer la propagation des r\u00e9sistances dans les Ehpad ou dans les foyers qui accueillent des animaux domestiques, ou encore dans le sol&nbsp;: tel est le troisi\u00e8me axe du Programme prioritaire de recherche (PPR) Antibior\u00e9sistance.<\/p>\n\n\n\n<p>3 des 14 projets financ\u00e9s dans le cadre du PPR Antibior\u00e9sistance pilot\u00e9 par l\u2019Inserm, pr\u00e9sent\u00e9s par leur porteur&nbsp;: Ora-Neat \u2013 Nelly Agrinier, DYASPEO \u2013 Jean-Yves Madec, MicroFlu4AMR \u2013 Andrew Griffiths, TheraEPI \u2013 Paola Arimondo.<\/p>\n\n\n\n<p>\u00c0 l\u2019initiative du minist\u00e8re de l\u2019Enseignement sup\u00e9rieur, de la Recherche et de l\u2019Innovation, et du Secr\u00e9tariat g\u00e9n\u00e9ral pour l\u2019investissement (SGPI), le PPR Antibior\u00e9sistance est dot\u00e9 de 40 millions d\u2019euros dans le cadre du troisi\u00e8me programme d\u2019investissements d\u2019avenir (PIA3).<\/p>\n\n\n\n<p>Ce programme de recherche qui f\u00e9d\u00e8re l\u2019ensemble des forces fran\u00e7aises publiques et priv\u00e9es du domaine, propose dans une approche \u00ab&nbsp;une seule sant\u00e9&nbsp;\u00bb, de nouvelles strat\u00e9gies et mesures de lutte pour inverser la courbe des r\u00e9sistances microbiennes. L\u2019Agence nationale de la recherche (ANR) est l\u2019op\u00e9rateur du programme.<\/p>\n\n\n\n<iframe src=\"https:\/\/pod.inserm.fr\/video\/1188-controler-lemergence-de-lantibioresistance-ppr-antibioresistance\/?is_iframe=true\" style=\"padding: 0; margin: 0; border:0\" allowfullscreen=\"\" width=\"100%\" height=\"360\"><\/iframe>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Innovation Therapeutique<\/strong><\/h4>\n\n\n\n<p>Les bact\u00e9ries\u2026 Depuis des millions d\u2019ann\u00e9es, elles ont la facult\u00e9 de s\u2019adapter aux toxines en d\u00e9veloppant des r\u00e9sistances\u2026 Un avantage \u00e9volutif certain. Et depuis que la m\u00e9decine a recours aux antibiotiques, ces r\u00e9sistances surviennent beaucoup plus vite. Le deuxi\u00e8me axe du Programme prioritaire de recherche (PPR) Antibior\u00e9sistance vise \u00e0 les prendre de vitesse et \u00e0 trouver des parades avec de nouveaux traitements.<\/p>\n\n\n\n<p>4 des 14 projets financ\u00e9s dans le cadre du PPR Antibior\u00e9sistance pilot\u00e9 par l\u2019Inserm, pr\u00e9sent\u00e9s par leur porteur&nbsp;: NASPEC \u2013 Michel Arthur, NAILR \u2013 Vincent Cattoir, PHAG-ONE \u2013 Frederic Laurent, TheraEPI \u2013 Paola Arimondo.<\/p>\n\n\n\n<p>\u00c0 l\u2019initiative du minist\u00e8re de l\u2019Enseignement sup\u00e9rieur, de la Recherche et de l\u2019Innovation, et du Secr\u00e9tariat g\u00e9n\u00e9ral pour l\u2019investissement (SGPI), le PPR Antibior\u00e9sistance est dot\u00e9 de 40 millions d\u2019euros dans le cadre du troisi\u00e8me programme d\u2019investissements d\u2019avenir (PIA3).<\/p>\n\n\n\n<p>Ce programme de recherche qui f\u00e9d\u00e8re l\u2019ensemble des forces fran\u00e7aises publiques et priv\u00e9es du domaine, propose dans une approche \u00ab&nbsp;une seule sant\u00e9&nbsp;\u00bb, de nouvelles strat\u00e9gies et mesures de lutte pour inverser la courbe des r\u00e9sistances microbiennes. L\u2019Agence nationale de la recherche (ANR) est l\u2019op\u00e9rateur du programme.<\/p>\n\n\n\n<iframe src=\"https:\/\/pod.inserm.fr\/video\/1186-innovation-therapeutique-ppr-antibioresistance\/?is_iframe=true\" style=\"padding: 0; margin: 0; border:0\" allowfullscreen=\"\" width=\"100%\" height=\"360\"><\/iframe>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Optimiser l&#8217;usage des antibiotiques en m\u00e9decine humaine et v\u00e9t\u00e9rinaire<\/strong><\/h4>\n\n\n\n<p>Les antibiotiques ont longtemps \u00e9t\u00e9 la solution miracle pour soigner les maladies infectieuse. Mais aujourd\u2019hui, de plus en plus de bact\u00e9ries leur r\u00e9sistent. Pourquoi&nbsp;? Comment pr\u00e9dire le comportement des bact\u00e9ries&nbsp;? Comment optimiser les traitements en m\u00e9decine humaine et v\u00e9t\u00e9rinaire&nbsp;?<\/p>\n\n\n\n<p>4 des 14 projets financ\u00e9s dans le cadre du Programme prioritaire de recherche (PPR) Antibior\u00e9sistance pilot\u00e9 par l\u2019Inserm, pr\u00e9sent\u00e9s par leur porteur&nbsp;: DREAM \u2013 Olivier Tenaillon, ANORUTI \u2013 Bruno Fantin\/Imane El Meouche, Seq2Diag \u2013 Philippe Glaser, MustArt \u2013 Alain Baulard.<\/p>\n\n\n\n<p>\u00c0 l\u2019initiative du minist\u00e8re de l\u2019Enseignement sup\u00e9rieur, de la Recherche et de l\u2019Innovation, et du Secr\u00e9tariat g\u00e9n\u00e9ral pour l\u2019investissement (SGPI), le PPR Antibior\u00e9sistance est dot\u00e9 de 40 millions d\u2019euros dans le cadre du troisi\u00e8me programme d\u2019investissements d\u2019avenir (PIA3).<\/p>\n\n\n\n<p>Ce programme de recherche qui f\u00e9d\u00e8re l\u2019ensemble des forces fran\u00e7aises publiques et priv\u00e9es du domaine, propose dans une approche \u00ab&nbsp;une seule sant\u00e9&nbsp;\u00bb, de nouvelles strat\u00e9gies et mesures de lutte pour inverser la courbe des r\u00e9sistances microbiennes. L\u2019Agence nationale de la recherche (ANR) est l\u2019op\u00e9rateur du programme.<\/p>\n\n\n\n<iframe src=\"https:\/\/pod.inserm.fr\/video\/1178-optimiser-lusage-des-antibiotiques-en-medecine-humaine-et-veterinaire-ppr-antibioresistance\/?is_iframe=true\" style=\"padding: 0; margin: 0; border:0\" allowfullscreen=\"\" width=\"100%\" height=\"360\"><\/iframe>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lors du colloque national sur l&#8217;Antibior\u00e9sistance, organis\u00e9 par l&#8217;Inserm le lundi 22 novembre \u00e0 Aubervilliers, ont \u00e9t\u00e9 diffus\u00e9s 5 vid\u00e9os documentaires, r\u00e9alis\u00e9es par la soci\u00e9t\u00e9 La Jolie Prod, que vous pouvez visionner ici : Gilles Bloch, p-dg de l\u2019Inserm et \u00c9velyne Jouvin-Marche, coordinatrice scientifique, pr\u00e9sentent le Programme prioritaire de recherche (PPR) Antibior\u00e9sistance Pourrait-on demain mourir [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":18931,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>5 films Inserm sur l&#039;antibior\u00e9sistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"5 films Inserm sur l&#039;antibior\u00e9sistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-30T18:21:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-24T09:34:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/11\/Film-cinema-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"858\" \/>\n\t<meta property=\"og:image:height\" content=\"381\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"5 films Inserm sur l&#8217;antibior\u00e9sistance\",\"datePublished\":\"2021-11-30T18:21:58+00:00\",\"dateModified\":\"2023-07-24T09:34:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/\"},\"wordCount\":1170,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/11\/Film-cinema-2.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/\",\"name\":\"5 films Inserm sur l'antibior\u00e9sistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/11\/Film-cinema-2.jpg\",\"datePublished\":\"2021-11-30T18:21:58+00:00\",\"dateModified\":\"2023-07-24T09:34:06+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/11\/Film-cinema-2.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/11\/Film-cinema-2.jpg\",\"width\":858,\"height\":381,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"5 films Inserm sur l\u2019antibior\u00e9sistance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"5 films Inserm sur l'antibior\u00e9sistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/","og_locale":"en_GB","og_type":"article","og_title":"5 films Inserm sur l'antibior\u00e9sistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2021-11-30T18:21:58+00:00","article_modified_time":"2023-07-24T09:34:06+00:00","og_image":[{"width":858,"height":381,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/11\/Film-cinema-2.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"5 films Inserm sur l&#8217;antibior\u00e9sistance","datePublished":"2021-11-30T18:21:58+00:00","dateModified":"2023-07-24T09:34:06+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/"},"wordCount":1170,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/11\/Film-cinema-2.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/","name":"5 films Inserm sur l'antibior\u00e9sistance - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/11\/Film-cinema-2.jpg","datePublished":"2021-11-30T18:21:58+00:00","dateModified":"2023-07-24T09:34:06+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/11\/Film-cinema-2.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/11\/Film-cinema-2.jpg","width":858,"height":381,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/5-films-inserm-sur-lantibioresistance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"5 films Inserm sur l\u2019antibior\u00e9sistance"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-14 00:30:14","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/18879"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=18879"}],"version-history":[{"count":22,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/18879\/revisions"}],"predecessor-version":[{"id":28833,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/18879\/revisions\/28833"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/18931"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=18879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=18879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=18879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}